Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Aflatoxin Poisoning × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5337 Neoplasms 4463 Prostatic Neoplasms 2485 Colorectal Neoplasms 2239 Carcinoma, Non-Small-Cell Lung 2228 Lung Neoplasms 1875 Multiple Myeloma 1389 Lymphoma 1338 Neoplasm Metastasis 1311 Leukemia, Myeloid, Acute 1277 Melanoma 1248 Pancreatic Neoplasms 1232 Ovarian Neoplasms 1191 Leukemia 1159 Head and Neck Neoplasms 1056 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1046 Lymphoma, Non-Hodgkin 1013 Colonic Neoplasms 962 Carcinoma, Hepatocellular 950 Stomach Neoplasms 945 Brain Neoplasms 901 Leukemia, Lymphocytic, Chronic, B-Cell 896 Rectal Neoplasms 827 Recurrence 807 Lymphoma, Follicular 804 Glioblastoma 775 Uterine Cervical Neoplasms 772 Carcinoma, Renal Cell 736 Lymphoma, Large B-Cell, Diffuse 698 Hodgkin Disease 646

Interventions

sodium calcium aluminosilicate, hydrated 1 Calcium Carbonate 1 ACCS100 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01677195 2016-04-19

RDMEACCS100

Texas Enterosorbents Incorporated

Phase 2 Completed

234 enrolled 7 charts

Aflatoxin Poisoning, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡